Company Profile
Cognition Therapeutics Stock Price, News & Analysis
- Ticker:
- CGTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.92 USD (-2.73%)
Close
Last updated: July 28, 2026
121M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, CGTX closed down 2.73% at $0.9235. No new same-company headline was identified in the current news window.
Company overview
Business overview
Cognition Therapeutics is a neuroscience company focused on neurodegenerative disease and synaptic biology. Its pipeline is aimed at difficult CNS disorders where new disease-modifying options are needed.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cognition sits in specialty neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical data, mechanistic validation, and the ability to create a differentiated CNS franchise.
Position Within the Biotechnology Landscape
Cognition is a high-catalyst neuroscience name whose valuation depends on early clinical outcomes.
Future catalysts
Cognition Therapeutics’s catalysts are zervimesine and the dementia program, with any clinical step that clarifies whether the asset can move forward in neurodegeneration. The company is still very readout-driven.
Recent news
- 01
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
Source: Cognition Therapeutics
- 02
- 03
- 04
Cognition Therapeutics Participating in Upcoming Investor Conferences
Source: Cognition Therapeutics
- 05
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
Source: Cognition Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cognition Therapeutics (CGTX)?
Cognition Therapeutics (CGTX) most recently closed at 0.92 USD, a -2.73% move versus the previous session.
What is the market cap of Cognition Therapeutics (CGTX)?
Cognition Therapeutics currently has a market capitalization of 121M USD on BioPharmSignal.
What does Cognition Therapeutics do?
Cognition Therapeutics is a neuroscience company focused on neurodegenerative disease and synaptic biology. Its pipeline is aimed at difficult CNS disorders where new disease-modifying options are needed.
On which exchange is CGTX stock listed?
Cognition Therapeutics (CGTX) is associated with NASDAQ, United States, Biopharma.
What is Cognition?
Cognition Therapeutics’s catalysts are zervimesine and the dementia program, with any clinical step that clarifies whether the asset can move forward in neurodegeneration.
Which conditions is Cognition Therapeutics targeting with Cognition?
Cognition Therapeutics is associated with neuroscience based on its company overview and current catalyst commentary.
How does Cognition Therapeutics describe recent progress with Cognition?
Cognition Therapeutics’s catalysts are zervimesine and the dementia program, with any clinical step that clarifies whether the asset can move forward in neurodegeneration.
What is Therapeutics?
Cognition Therapeutics is a neuroscience company focused on neurodegenerative disease and synaptic biology.